This Analyst Just Downgraded Their Shanghai INT Medical Instruments Co., Ltd. (HKG:1501) EPS Forecasts
This Analyst Just Downgraded Their Shanghai INT Medical Instruments Co., Ltd. (HKG:1501) EPS Forecasts
Today is shaping up negative for Shanghai INT Medical Instruments Co., Ltd. (HKG:1501) shareholders, with the covering analyst delivering a substantial negative revision to this year's forecasts. Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analyst seeing grey clouds on the horizon.
今天對上海英泰醫療器械有限公司(HKG: 1501)的股東來說是負數,封面分析師對今年的預測進行了大幅的負面修正。收入和每股收益(EPS)的預測均向下修正,分析師認爲灰雲即將出現。
Following the downgrade, the current consensus from Shanghai INT Medical Instruments' solitary analyst is for revenues of CN¥979m in 2024 which - if met - would reflect a major 30% increase on its sales over the past 12 months. Per-share earnings are expected to surge 34% to CN¥1.16. Prior to this update, the analyst had been forecasting revenues of CN¥1.2b and earnings per share (EPS) of CN¥1.36 in 2024. It looks like analyst sentiment has declined substantially, with a measurable cut to revenue estimates and a real cut to earnings per share numbers as well.
降級之後,上海英泰醫療器械的獨立分析師目前的共識是,2024年的收入爲9.79億元人民幣,如果達到,這將反映其在過去12個月中銷售額的30%的大幅增長。預計每股收益將激增34%,至1.16元人民幣。在本次更新之前,該分析師一直預測2024年的收入爲12億元人民幣,每股收益(EPS)爲1.36元人民幣。看來分析師的情緒已大幅下降,收入預期大幅下調,每股收益數字也實際下調。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240324/0-d097fe87c25dedac7b9b836c505a02eb-0-17eafa90e8202ba76b94d912260bfe50.png/big)
The analyst made no major changes to their price target of CN¥32.25, suggesting the downgrades are not expected to have a long-term impact on Shanghai INT Medical Instruments' valuation.
該分析師沒有對32.25元人民幣的目標股價做出重大調整,這表明下調評級預計不會對上海英泰醫療儀器的估值產生長期影響。
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Shanghai INT Medical Instruments' past performance and to peers in the same industry. It's clear from the latest estimates that Shanghai INT Medical Instruments' rate of growth is expected to accelerate meaningfully, with the forecast 30% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 24% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 23% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Shanghai INT Medical Instruments is expected to grow much faster than its industry.
這些估計很有趣,但是在查看預測與上海INT醫療器械過去的表現以及與同一行業的同行進行比較時,可以更粗略地描述一些細節。從最新估計中可以明顯看出,上海英泰醫療器械的增長率預計將大幅加快,預計到2024年底的年化收入增長30%,將明顯快於過去五年中每年24%的歷史增長。相比之下,同行業的其他公司預計收入每年將增長23%。考慮到收入增長的預測,很明顯,上海英泰醫療器械的增長速度預計將比其行業快得多。
The Bottom Line
底線
The biggest issue in the new estimates is that the analyst has reduced their earnings per share estimates, suggesting business headwinds lay ahead for Shanghai INT Medical Instruments. While the analyst did downgrade their revenue estimates, these forecasts still imply revenues will perform better than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on Shanghai INT Medical Instruments after the downgrade.
新估計中最大的問題是,分析師下調了每股收益預期,這表明上海英泰醫療器械面臨業務不利因素。儘管分析師確實下調了收入預期,但這些預測仍然意味着收入表現將好於整個市場。我們還驚訝地看到目標股價保持不變。儘管如此,業務狀況仍在惡化(假設預測準確!)可以成爲股價的主要指標,因此我們不會責怪投資者在降級後對上海英泰醫療器械更加謹慎。
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At least one analyst has provided forecasts out to 2026, which can be seen for free on our platform here.
話雖如此,公司收益的長期軌跡比明年重要得多。至少有一位分析師提供了到2026年的預測,可以在我們的平台上免費查看。
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
當然,看到公司管理層將大量資金投資於股票與了解分析師是否在下調預期一樣有用。因此,您可能還希望搜索這份內部人士正在購買的免費股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。